<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1113">
  <stage>Registered</stage>
  <submitdate>28/03/2006</submitdate>
  <approvaldate>28/03/2006</approvaldate>
  <nctid>NCT00308503</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia</studytitle>
    <scientifictitle>Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study</scientifictitle>
    <utrn />
    <trialacronym>EPOCH</trialacronym>
    <secondaryid>EFC6220</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sleep Initiation and Maintenance Disorders</healthcondition>
    <healthcondition>Insomnia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - eplivanserin (SR46349)
Treatment: drugs - placebo

Experimental: 1 - 5 mg/day

Placebo Comparator: 2 - 


Treatment: drugs: eplivanserin (SR46349)
oral administration

Treatment: drugs: placebo
oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)</outcome>
      <timepoint>week 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)</outcome>
      <timepoint>week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in patient reported wake after sleep onset (pr-WASO)</outcome>
      <timepoint>week 6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month
             preceding the study visit.

          -  Disturbance of sleep maintenance:

               -  Based on patient' s information:

                    -  Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed,
                       each night, over the preceding two weeks,

                    -  Patient must complain of at least one hour of wakefulness after sleep onset
                       for at least 3 nights per week over the preceding month,

                    -  Patient must report impact on daytime functioning associated with sleep
                       maintenance insomnia

        Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the
        sleep laboratory during the two screening nights.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Females who are lactating or who are pregnant, or of childbearing potential not using
             an acceptable form of contraception

          -  Patients presenting with acute or chronic pain resulting in insomnia

          -  Patients with current psychiatric disturbances

          -  Body mass index &gt; 32

          -  Evidence of any clinically significant, severe or unstable, acute or chronically
             progressive medical or surgical disorder, or any condition that may interfere with the
             absorption, metabolism, distribution or excretion of the study drug, or may affect
             patient safety

          -  Clinically significant and abnormal electrocardiogram (ECG) (including QTc B &gt; 500ms),

          -  A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C
             virus [HCV] antibodies)

          -  Positive qualitative urine drug screen at screening

          -  Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising
             usually more than 5 cups or glasses per day

          -  Use of any over-the-counter or prescription sleep medication, or of any substance with
             psychotropic effects or properties known to affect sleep/wake, within one week or five
             half-lives (whichever is longer), prior to screening

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  Based on medical history and/or NPSG:

               -  primary hypersomnia

               -  narcolepsy

               -  breathing-related sleep disorder (apnea-hypopnea index &gt; 10/hour of sleep)

               -  circadian rhythm sleep disorder

               -  parasomnia (e.g. somnambulism)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>608</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sanofi-Aventis - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance
      of patients with primary insomnia using night polysomnography recordings over a 6-week
      treatment period corresponding to a stabilization of improvement of sleep.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00308503</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>